Distribution Agreement Announced for Zemcelpro® in Key International Markets including Argentina, Hong Kong, and Singapore

ExCellThera and FarmaMondo: Expanding the Reach of Zemcelpro®

Introduction

In an important development for the field of hematological treatments, ExCellThera Inc., a pioneering company in blood stem cell expansion technologies, has teamed up with FarmaMondo SA to distribute its groundbreaking product, Zemcelpro® (also known as dorocubicel). This collaboration targets key markets—Argentina, Hong Kong, and Singapore—thereby broadening access to innovative therapies for patients with unmet medical needs.

Details of Zemcelpro®

Zemcelpro® is a novel personalized transplant product that offers a unique combination of CD34+ expanded cells treated with UM171 (dorocubicel) and non-expanded CD34- cells, all originating from the same umbilical cord blood unit. It has recently received conditional marketing authorization from the European Commission, specifically for adult patients suffering from hematological malignancies that necessitate allogeneic hematopoietic stem cell transplant following myeloablative conditioning.

The significance of this product lies in its ability to meet the needs of patients when compatible donors are not available, addressing a critical gap in current treatment protocols.

Strategic Implications

Under the agreement, FarmaMondo will leverage its extensive experience in regulatory services and market access to support early access programs for Zemcelpro® within the specified territories. This partnership not only facilitates availability but also fosters responsible patient access through applicable early access pathways in the targeted regions.

David Millette, CEO of Cordex, highlighted the importance of this strategic partnership, stating, “This agreement with FarmaMondo marks a significant milestone in our early access strategy and underscores our continuous commitment to advance Zemcelpro® for patients with substantial unmet medical needs.” His remarks reflect the growing demand among healthcare professionals and transplantation centers for innovative therapies that address chronic issues related to hematological cancers and stem cell transplants.

On the other hand, Yaron Spigel, CEO of FarmaMondo, expressed enthusiasm about the alliance, remarking, “Partnering with Cordex to facilitate access to Zemcelpro® is in alignment with FarmaMondo's mission to ensure eligible patients receive innovative, life-saving medications in markets where access pathways may be complex.” This synergy aims to provide essential support to healthcare providers and transplant centers, optimizing the delivery of cutting-edge treatments.

Ongoing Research and Future Outlook

Zemcelpro® has undergone rigorous clinical evaluations, having been tested in over 120 patients with hematologic disorders across clinical trials conducted in the US, Europe, and Canada. The product has successfully obtained orphan drug designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA in the United States, alongside priority medicine designation in Europe (EMA).

As part of its ongoing commitment to advancing medical innovations, ExCellThera continues to explore additional regulatory submissions in other jurisdictions, including the United States, Canada, the United Kingdom, and Switzerland. Future efforts will include pivotal Phase 3 trials targeting patients with acute leukemias and high-risk myelodysplasia, particularly those with limited treatment options.

Conclusion

The partnership between ExCellThera and FarmaMondo represents a progressive step toward enhancing patient access to groundbreaking treatments like Zemcelpro®. With the focus on international distribution, this collaboration promises to address longstanding issues in treating hematological diseases while embracing a patient-centric approach to healthcare.

For further information on Zemcelpro® and its therapeutic applications, including warnings and precautions, please refer to the product’s Summary of Product Characteristics (SmPC) in the EU framework.

If you're interested in following the innovative developments of ExCellThera, you can visit their website or follow them on LinkedIn for the latest updates on their therapeutic advancements.